Drug Patents owned by Myovant Sciences
1. List of Myfembree drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(11 months from now) | |
| US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9346822 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 7 days from now) | |
| US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
| New Product (NP) | May 26, 2024 |
| New Indication (I) | Aug 5, 2025 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET;ORAL
MYFEMBREE family patents
20
United States
8
Japan
8
European Union
5
Australia
4
Israel
4
China
4
Canada
3
Morocco
3
Brazil
3
Mexico
3
Argentina
3
EA
3
New Zealand
2
Poland
2
Lithuania
2
Spain
2
Slovenia
2
Hungary
2
Portugal
2
Norway
2
Denmark
1
Hong Kong
1
RS
1
Korea, Republic of
1
Netherlands
1
Moldova, Republic of
1
Cyprus
1
South Africa
1
Colombia
1
Russia
1
Croatia
1
Taiwan, Province of China
2. List of Orgovyx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(11 months from now) | |
| US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735401 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(11 months from now) | |
| US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(13 years from now) | |
| US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
ORGOVYX family patents
23
United States
11
Japan
9
European Union
6
Australia
5
Israel
5
China
5
Canada
4
Brazil
4
Mexico
4
New Zealand
3
Morocco
3
Argentina
3
EA
2
Poland
2
Lithuania
2
Spain
2
Slovenia
2
Hungary
2
Portugal
2
Norway
2
Taiwan, Province of China
2
Denmark
1
Hong Kong
1
RS
1
Korea, Republic of
1
Malaysia
1
Netherlands
1
Moldova, Republic of
1
Cyprus
1
South Africa
1
Colombia
1
Russia
1
Croatia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic